AbnomX Announces the Release of Antibody-Extractor™ 11 with HumanizerAI Belgium, February 15, 2025 – AbnomX unveils Antibody-Extractor™ 11, a groundbreaking upgrade to its Antibody-Extractor™ (AE) platform, integrating cutting-edge technology to enhance antibody design, humanization, and analysis. At the core of this release is HumanizerAI, our in-house AI...
BioLizard’s custom advanced analytics services complement AbnomX’s innovative, user-friendly platform for deciphering immune repertoire data. GHENT, Belgium April 2nd, 2024 - AbnomX and BioLizard announced a strategic partnership today. AbnomX are pioneers in the industrialization of antibody discovery and have developed their Antibody-Extractor platform to support...
We are thrilled to announce the release of Antibody-Extractor 10.1, an upgrade that introduces powerful features to enhance your experience with our platform. This release comes with an advanced Antibody Items and Sequences Mining tool, offering unprecedented capabilities for querying and linking sequences to experimental...
Unlock the power of seamless antibody sequence management and experimental result linkage with Abigael, a cutting-edge, highly flexible data platform system integrated with the state-of-the-art Antibody-Extractor. Tailored for researchers, scientists, and software developers, this comprehensive solution streamlines the organization and analysis of antibody sequences, offering...
AbnomX is pleased to welcome PRECIRIX, a clinical-stage biotechnology company developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The single-domain antibody targets the cancer in minutes after IV infusion anywhere in the body. PRECIRIX will use the Antibody-Extractor™ algorithms with dedicated VHH functionality to...
While we were onboarding a slew of new users, we have also been busy upgrading our lead software platform. Let’s start with our favorite new feature: the Antibody Sequence Editor. One of our most highly requested features. Antibody-Extractor can now display antibody sequences in an interactive graphical...
AbnomX is pleased to welcome QVQ, a company providing extensive expertise in each step of lead panel VHH development, ranging from immunization, selection and screening to large scale production. QVQ will use the Antibody-Extractor™ algorithms with dedicated VHH functionality to strengthen its services to its...
AbnomX welcomes BAC B.V., a part of Thermo Fisher Scientific, among its growing list of users of the Antibody-Extractor™. BAC is the original developer of the CaptureSelect affinity chromatography products, based on Camelid-derived single domain [VHH] antibody fragments. BAC can now make good use of the...
In this use case we describe a novel in-silico antibody discovery methodology called “In vitro maturation”. The methodology was successfully used by the company argenx....
AbnomX is pleased to welcome the University of Lisbon as a new user of Antibody-Extractor....